- $53.70m
- $44.23m
- $1.12m
Brief: Renovorx Reports Full Year 2022 Financial Results And Achievement Of Important Phase III Clinical Study Milestone
Brief: RenovoRx Announces Initial Results In Pharmacokinetic Substudy
Brief: RenovoRx Strengthens IP Portfolio With Eighth U.S. Patent
Brief: Renovorx Reports Third Quarter 2022 Financial Results
Brief: Renovorx Inc Files For Mixed Shelf Of Up To $50 Mln - SEC Filing
Brief: Renovorx Announces Presentation At Symposium On Clinical Interventional Oncology (CIO) Highlighting Its Innovative Therapy Platform For Targeted Treatment Of Pancreatic Cancer
Brief: RenovoRx Appoints Angela Gill Nelms As Chief Operating Officer
Brief: RenovoRx reports Q2 results
Brief: RenovoRx Appoints James Ahlers As CFO
Brief: RenovoRx to Present Preclinical Data For Its Platform's Potential Utility for Bile Duct Cancer Treatment
Brief: RenovoRx Reports Q1 2022 Financial Results
Brief: RenovoRx Reports Full Year 2021 Financial Results
Brief: Renovorx Enrolls First Patient In Ongoing Tiger-Pac Phase 3 Clinical Trial
Brief: RenovoRx Says As Of Sept 30, Co Had Cash, Cash Equivalents Of $17.7 Mln And No Outstanding Debt Obligations
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 01:01 PM
U.S. STOCKS ON THE MOVE-PubMatic, Unity Biotech, Seres Therapeutics
U.S. STOCKS ON THE MOVE-RingCentral, Open Lending, Wendy's
RenovoRx surges on social media chatter, pancreatic cancer presentation
U.S. STOCKS ON THE MOVE-Boeing, BioMarin, Shutterstock